Literature DB >> 25603857

Tumor necrosis-initiated complement activation stimulates proliferation of medulloblastoma cells.

Adrian J Maurer1, Phillip A Bonney, Lucas C Toho, Chad A Glenn, Shweta Agarwal, James D Battiste, Kar-Ming Fung, Michael E Sughrue.   

Abstract

OBJECTIVE AND
DESIGN: We sought to determine the effect of necrosis-induced activation of the complement protein C3 in medulloblastoma. MATERIALS/
METHODS: Twelve medulloblastoma surgical specimens were evaluated for complement activation using immunohistochemistry, with H&E stains performed on adjacent tissue sections to determine the relationship of complement activation to necrotic tissue. Flow cytometry and Western blot were performed on three established medulloblastoma lines and one surgically-procured cell culture to determine expression of C3a receptor (C3aR) in medulloblastoma. In vitro proliferation of siRNA C3aR knockdown cells was compared to that of control siRNA cells with cell line Daoy.
RESULTS: Three surgical specimens were found to have necrosis on H&E sections. In each case, iC3b staining was identified on adjacent sections, limited to the necrotic region. In no case did necrosis occur without iC3b staining on adjacent sections. C3aR protein was demonstrated on both the three established cell lines and on the surgical culture. Proliferation assays of Daoy cells with siRNA knockdown vs. control siRNA revealed significantly reduced proliferation at 72 h (p = 0.001).
CONCLUSIONS: Necrosis is associated with complement activation in medulloblastoma. Medulloblastoma cells express C3aR, and siRNA-mediated knockdown of C3aR inhibits proliferation of these cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25603857      PMCID: PMC6192526          DOI: 10.1007/s00011-015-0796-y

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  37 in total

Review 1.  Complement components of the innate immune system in health and disease in the CNS.

Authors:  P Gasque; Y D Dean; E P McGreal; J VanBeek; B P Morgan
Journal:  Immunopharmacology       Date:  2000-08

Review 2.  Complement and the central nervous system: emerging roles in development, protection and regeneration.

Authors:  Martin J Rutkowski; Michael E Sughrue; Ari J Kane; Steven A Mills; Shanna Fang; Andrew T Parsa
Journal:  Immunol Cell Biol       Date:  2010-04-20       Impact factor: 5.126

3.  The C3a receptor antagonist SB 290157 has agonist activity.

Authors:  Marie-Claude Mathieu; Nicole Sawyer; Gillian M Greig; Martine Hamel; Stacia Kargman; Yves Ducharme; Cheuk K Lau; Richard W Friesen; Gary P O'Neill; Francois G Gervais; Alex G Therien
Journal:  Immunol Lett       Date:  2005-03-25       Impact factor: 3.685

4.  C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins.

Authors:  J Elsner; M Oppermann; W Czech; A Kapp
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

Review 5.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

6.  Complement: a novel factor in basal and ischemia-induced neurogenesis.

Authors:  Yalda Rahpeymai; Max Albert Hietala; Ulrika Wilhelmsson; Andrew Fotheringham; Ioan Davies; Ann-Katrin Nilsson; Jörg Zwirner; Rick A Wetsel; Craig Gerard; Milos Pekny; Marcela Pekna
Journal:  EMBO J       Date:  2006-02-23       Impact factor: 11.598

7.  The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children.

Authors:  Nicolas R Smoll; Katharine J Drummond
Journal:  J Clin Neurosci       Date:  2012-09-13       Impact factor: 1.961

8.  Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM.

Authors:  Caroline L F Ciurana; Bas Zwart; Gerard van Mierlo; C Erik Hack
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

9.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.

Authors:  Dawn Elizabeth McNeil; Timothy R Coté; Limin Clegg; Lucy Balian Rorke
Journal:  Med Pediatr Oncol       Date:  2002-09

10.  Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management.

Authors:  G Kopelson; R M Linggood; G M Kleinman
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

View more
  3 in total

1.  Tissue necrosis and its role in cancer progression.

Authors:  Adi Karsch-Bluman; Ariel Feiglin; Eliran Arbib; Tal Stern; Hila Shoval; Ouri Schwob; Michael Berger; Ofra Benny
Journal:  Oncogene       Date:  2018-11-02       Impact factor: 9.867

2.  Complement C3a activates astrocytes to promote medulloblastoma progression through TNF-α.

Authors:  Biao Gong; Duancheng Guo; Chaonan Zheng; Zhen Ma; Jie Zhang; Yanghui Qu; Xinhua Li; Gen Li; Li Zhang; Yuan Wang
Journal:  J Neuroinflammation       Date:  2022-06-20       Impact factor: 9.587

3.  Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas.

Authors:  Yu Hou; Huahu Guo; Chen Cao; Xianlong Li; Boqiang Hu; Ping Zhu; Xinglong Wu; Lu Wen; Fuchou Tang; Yanyi Huang; Jirun Peng
Journal:  Cell Res       Date:  2016-02-23       Impact factor: 25.617

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.